<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-24600" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Extranodal NK-Cell Lymphoma</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Thida</surname>
            <given-names>Aye M.</given-names>
          </name>
          <aff>New York Health + Hospitals/Woodhull</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Gohari</surname>
            <given-names>Pouyan</given-names>
          </name>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Aye Thida declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Pouyan Gohari declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>17</day>
          <month>7</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-24600.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Extranodal NK/T-cell lymphoma, nasal type, is a rare subtype of non-Hodgkin lymphoma. Patients commonly present with a nasal mass, nasal obstruction, or nasal bleeding. With the application of modern therapies, clinical outcomes of patients with this disease have improved significantly. This activity describes the evaluation and management of extranodal NK/T-cell lymphoma, nasal type, and reviews the role of the interprofessional team in evaluating and treating patients with this disease.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the etiology of extranodal NK/T-cell lymphoma.</p></list-item><list-item><p>Describe the evaluation of extranodal NK/T-cell lymphoma.</p></list-item><list-item><p>Outline the management options available for extranodal NK/T-cell lymphoma.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=24600&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=24600">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-24600.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Extranodal NK/T-cell lymphoma, nasal type, is a rare subtype of non-Hodgkin lymphoma,&#x000a0;characterized by a universal association with Epstein-Barr virus (EBV),&#x000a0;and disfiguring clinical presentations.<xref ref-type="bibr" rid="article-24600.r1">[1]</xref><xref ref-type="bibr" rid="article-24600.r2">[2]</xref><xref ref-type="bibr" rid="article-24600.r3">[3]</xref>&#x000a0;With the application of modern therapies, the clinical outcomes of these patients have improved significantly.<xref ref-type="bibr" rid="article-24600.r4">[4]</xref>&#x000a0;Nevertheless, survival is still heavily dependent on the type of disease and stage at diagnosis.</p>
      </sec>
      <sec id="article-24600.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Irrespective of the ethnic origin of patients, there is a strong association of EBV infection in almost all cases of extranodal NK/T-cell lymphoma, suggesting an important role of the virus in the etiology of this disease.<xref ref-type="bibr" rid="article-24600.r2">[2]</xref><xref ref-type="bibr" rid="article-24600.r5">[5]</xref><xref ref-type="bibr" rid="article-24600.r6">[6]</xref><xref ref-type="bibr" rid="article-24600.r7">[7]</xref><xref ref-type="bibr" rid="article-24600.r8">[8]</xref><xref ref-type="bibr" rid="article-24600.r9">[9]</xref></p>
      </sec>
      <sec id="article-24600.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Extranodal NK/T-cell lymphoma is regarded as a rare subtype of non-Hodgkin lymphoma.<xref ref-type="bibr" rid="article-24600.r1">[1]</xref>&#x000a0;The disease is more prevalent in Asian countries than in Europe and the United States.<xref ref-type="bibr" rid="article-24600.r4">[4]</xref>&#x000a0;It often affects adults and is more common in men than in women.</p>
      </sec>
      <sec id="article-24600.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Genetic abnormalities, EBV infection, and tumor microenvironment have been shown to play significant roles in the molecular pathogenesis of extranodal NK/T-cell lymphoma.<xref ref-type="bibr" rid="article-24600.r10">[10]</xref><xref ref-type="bibr" rid="article-24600.r11">[11]</xref></p>
        <p>
<bold>1. Genetic Abnormalities</bold>
</p>
        <p>
<bold>JAK/STAT Pathway</bold>
</p>
        <p>The Janus kinase/signal transducers and activators of transcription (JAK/STAT) pathway is important for hematopoiesis and immune development. In extranodal NK/T-cell lymphoma, STAT3 of the JAK/STAT cascade is the most frequently mutated genes followed by TP53, JAK3, JAK1, and SOCS1.<xref ref-type="bibr" rid="article-24600.r12">[12]</xref><xref ref-type="bibr" rid="article-24600.r13">[13]</xref><xref ref-type="bibr" rid="article-24600.r14">[14]</xref><bold>&#x000a0;</bold>STAT3 mutations promote STAT3 phosphorylation and transcriptional activity of STAT3 in the absence of cytokines. By binding to the programmed cell death-ligand 1 (PD-L1) gene promoter, activated STAT3 then upregulates the expression of PD-L1. Increased PD-L1 interacts with the programmed cell death protein 1 (PD-1), an inhibitory co-receptor on T-cells, and suppresses T-cell activation and receptor signaling.<xref ref-type="bibr" rid="article-24600.r15">[15]</xref>&#x000a0;This leads to T-cell exhaustion which favors tumor cell survival.</p>
        <p>
<bold>Epigenetic Dysregulation</bold>
</p>
        <p>Enhancer of zeste homolog 2 (EZH2) is a histone methyltransferase and a catalytic component of the polycomb repressive complex 2 (PRC2) molecule.<xref ref-type="bibr" rid="article-24600.r16">[16]</xref>&#x000a0;The PRC2 molecule is one of the polycomb group proteins that form chromatin-modifying complexes essential for embryonic development and stem cell renewal but are commonly deregulated in cancer.</p>
        <p>EZH2 is aberrantly overexpressed in extranodal NK/T-cell lymphoma, which is mediated by MYC-induced repression of regulatory microRNAs.<xref ref-type="bibr" rid="article-24600.r17">[17]</xref><xref ref-type="bibr" rid="article-24600.r18">[18]</xref><xref ref-type="bibr" rid="article-24600.r19">[19]</xref>&#x000a0;It exerts its oncogenic function by inducing gene repression through its effect on chromatin via its histone methyltransferase activity, and by promoting the transcription of cyclin D1.</p>
        <p>Besides, phosphorylation by JAK3 promotes EZH2 as a transcriptional activator.<xref ref-type="bibr" rid="article-24600.r20">[20]</xref>&#x000a0;Through the upregulation of genes involved in DNA replication, cell cycle, biosynthesis, stemness, and invasiveness, phosphorylated EZH2 promotes a higher proliferative capacity of the tumor cells.</p>
        <p>
<bold>PD-L1 Genetic Abnormalities</bold>
</p>
        <p>Structural variations and focal copy number alterations affecting PD-L1 are associated with an overexpression of PD-L1 in extranodal NK/T-cell lymphoma.<xref ref-type="bibr" rid="article-24600.r21">[21]</xref></p>
        <p>
<bold>Hereditary Susceptibility</bold>
</p>
        <p>A genome-wide association study found out that a single-nucleotide polymorphism located in HLA-DPB1, namely rs9277378, was associated with a 2.3 times higher risk of extranodal NK/T-cell lymphoma compared to baseline, rendering its hereditary susceptible to the disease.<xref ref-type="bibr" rid="article-24600.r22">[22]</xref></p>
        <p>
<bold>Other Gene Mutations</bold>
</p>
        <p>Extranodal NK/T-cell lymphoma is associated with the deletion in the chromosome 6q21-25,&#x000a0;and mutations in the cell surface receptor FAS (Apo-1/CD95), p53, K-ras, and c-kit.<xref ref-type="bibr" rid="article-24600.r23">[23]</xref><xref ref-type="bibr" rid="article-24600.r24">[24]</xref><xref ref-type="bibr" rid="article-24600.r25">[25]</xref><xref ref-type="bibr" rid="article-24600.r26">[26]</xref><xref ref-type="bibr" rid="article-24600.r27">[27]</xref><xref ref-type="bibr" rid="article-24600.r28">[28]</xref><xref ref-type="bibr" rid="article-24600.r29">[29]</xref><xref ref-type="bibr" rid="article-24600.r30">[30]</xref><xref ref-type="bibr" rid="article-24600.r31">[31]</xref><xref ref-type="bibr" rid="article-24600.r32">[32]</xref><xref ref-type="bibr" rid="article-24600.r33">[33]</xref></p>
        <p>
<bold>2. EBV Infection</bold>
</p>
        <p>EBV infection is believed to play an important role in the pathogenesis of extranodal NK/T-cell lymphoma though its actual mechanism is still undetermined. It is known to integrate its genomic fragment into different repeat families of the human genome, such as SINE, LINE, and satellite.<xref ref-type="bibr" rid="article-24600.r34">[34]</xref>&#x000a0;By integrating its genomic fragment into the intron of the human non-homologous end-joining factor 1 (NHEJ1) gene, EBV downregulates NHEJ1, which is an important DNA repair factor for the NHEJ pathway that mediates repair of double-stranded breaks. This results in genome-wide instability with the onset of extranodal NK/T-cell lymphoma.</p>
        <p>By expressing EBV nuclear antigen 1 (EBNA1), latent membrane protein (LMP) 1, LMP2A, and LMP2B (latency phase II), EBV modulates cell signaling, and forms barriers to apoptotic signals to escape from T-cell-mediated immune response.<xref ref-type="bibr" rid="article-24600.r35">[35]</xref>&#x000a0;Besides, the EBV BART RNAs, which are highly transcribed in extranodal NK/T-cell lymphoma, is thought to play an important role in driving the disease and immune evasion.<xref ref-type="bibr" rid="article-24600.r34">[34]</xref></p>
        <p>
<bold>3. Tumor Microenvironment</bold>
</p>
        <p>Chemokines play a crucial role in the proliferation of tumor cells with the recruitment of inflammatory cells.<xref ref-type="bibr" rid="article-24600.r36">[36]</xref><xref ref-type="bibr" rid="article-24600.r37">[37]</xref>&#x000a0;Tumor cells secrete IP-10 (interferon gamma-induced protein 10), CCL2 (C-C motif chemokine ligand 2), and CCL22 (C-C motif chemokine ligand 22) which are monocyte-attractant chemokines. Monocytes, in turn, promote proliferation, LMP-1 expression, and IP-10 production of tumor cells via membrane-bound IL-15/IL-15 receptor alpha complex. This positive feedback loop between tumor cells and monocytes may contribute to lymphoma progression.</p>
      </sec>
      <sec id="article-24600.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>Angioinvasiveness and necrosis are distinguishing pathologic features in most cases of extranodal NK/T-cell lymphoma.<xref ref-type="bibr" rid="article-24600.r38">[38]</xref>&#x000a0;Surrounded by various inflammatory cells such as granulocytes, lymphocytes, monocytes, and macrophages, the lymphoma cells are usually medium-sized or a mixture of small and large cells. They usually reveal surface CD3&#x02212;, cytoplasmic CD3&#x003b5;+, CD56+, CD16+/&#x02212;, and germline T-cell receptor (TCR) on immunophenotyping, demonstrating NK-cell lineage. In a subset of lymphoma cells of T-cell origin, positive surface CD3 and negative CD56 may be detected. EBV-encoded RNA in situ hybridization (EBER-ISH) and cytotoxic granule protein TIA-1 are always positive.</p>
      </sec>
      <sec id="article-24600.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Most patients with extranodal NK/T-cell lymphoma are of nasal type, which is localized to the upper aerodigestive tract.<xref ref-type="bibr" rid="article-24600.r3">[3]</xref>&#x000a0;They commonly present with a nasal mass, nasal obstruction, or nasal bleeding. Other clinical presentations include hoarseness of voice, dysphagia, halitosis, airway obstruction, and dysphonia. Bone marrow involvement is not common in initial presentation.<xref ref-type="bibr" rid="article-24600.r39">[39]</xref>&#x000a0;</p>
        <p>In patients with an extranasal involvement, skin, testis, and gastrointestinal (GI) tract are typically affected.<xref ref-type="bibr" rid="article-24600.r2">[2]</xref><xref ref-type="bibr" rid="article-24600.r40">[40]</xref>&#x000a0;Abdominal pain, GI bleeding, and bowel perforation are the most common presentations in patients with GI involvement.</p>
      </sec>
      <sec id="article-24600.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>A definitive diagnosis requires an adequate biopsy with histopathological and immunohistochemical examinations. It is followed by proper staging with positron emission tomography/computed tomography (PET/CT) scans to assess the extent of the disease and to guide therapy.<xref ref-type="bibr" rid="article-24600.r41">[41]</xref>&#x000a0;Contrast-enhanced&#x000a0;CT scans and magnetic resonance imaging scans can also be used.&#x000a0;The PET/CT results are interpreted using the 2014 Lugano classification as follows:<xref ref-type="bibr" rid="article-24600.r42">[42]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Stage I: a single lymph node, a group of adjacent lymph nodes or single extranodal lesions without nodal involvement</p>
          </list-item>
          <list-item>
            <p>Stage II: two or more lymph node groups on the same side of the diaphragm or limited contiguous extranodal involvement</p>
          </list-item>
          <list-item>
            <p>Stage II bulky: stage II as above with a bulky feature defined as a single nodal mass of 10 centimeters or greater than a third of the transthoracic diameter</p>
          </list-item>
          <list-item>
            <p>Stage III: nodes on both sides of diaphragm or nodes above diaphragm with spleen involvement</p>
          </list-item>
          <list-item>
            <p>Stage IV: additional noncontiguous extralymphatic involvement</p>
          </list-item>
        </list>
        <p>A useful prognostic model for patients with extranodal NK/T-cell lymphoma is the prognostic index of natural killer lymphoma (PINK), which includes age above&#x02009;60&#x02009;years, stage III to IV disease, distant lymph node involvement, and non-nasal disease.<xref ref-type="bibr" rid="article-24600.r43">[43]</xref>&#x000a0;A modified PINK model that includes EBV-DNA viral load at the time of diagnosis (PINK-E) can also be used. EBV-DNA viral load by quantitative PCR correlates well with clinical stage, treatment response, and prognosis; therefore, it plays an important role in the diagnosis and monitoring of the disease.<xref ref-type="bibr" rid="article-24600.r44">[44]</xref><xref ref-type="bibr" rid="article-24600.r45">[45]</xref></p>
      </sec>
      <sec id="article-24600.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>The therapeutic approach of extranodal NK/T-cell lymphoma is based on several factors, such as the age of patients, the extent of disease, potential toxicities, and survivorship.</p>
        <p>
<bold>1. Induction Therapy</bold>
</p>
        <p>
<bold>Nasal Disease (Stage I&#x02013;II)</bold>
</p>
        <p>Patients with nasal disease (stage I&#x02013;II) may be treated with concurrent chemoradiotherapy (CRT) regimens such as DeVIC (dexamethasone, etoposide, ifosfamide, and carboplatin) with radiation therapy (RT),&#x000a0;or VIPD (etoposide, ifosfamide, cisplatin, dexamethasone) with RT.<xref ref-type="bibr" rid="article-24600.r46">[46]</xref><xref ref-type="bibr" rid="article-24600.r47">[47]</xref><xref ref-type="bibr" rid="article-24600.r48">[48]</xref><xref ref-type="bibr" rid="article-24600.r49">[49]</xref>&#x000a0;Other regimens that may be considered include sequential CRT with modified SMILE [dexamethasone (steroid), methotrexate, ifosfamide, pegaspargase, and etoposide] with RT,&#x000a0;and sandwich CRT with P-GEMOX (pegaspargase, gemcitabine, and oxaliplatin) with RT.<xref ref-type="bibr" rid="article-24600.r50">[50]</xref><xref ref-type="bibr" rid="article-24600.r51">[51]</xref><xref ref-type="bibr" rid="article-24600.r52">[52]</xref>&#x000a0;For patients who are unfit for chemotherapy, RT alone may be considered.<xref ref-type="bibr" rid="article-24600.r53">[53]</xref></p>
        <p>
<bold>Nasal Disease (Stage IV) and Extranasal Disease (Stage I&#x02013;IV)</bold>
</p>
        <p>Pegaspargase-based combination chemotherapy regimens such as AspaMetDex (L-asparaginase, methotrexate, and dexamethasone),&#x000a0;modified SMILE,&#x000a0;or P-GEMOX, with or without RT may be considered in patients with nasal disease (stage IV) or extranasal disease (stage I&#x02013;IV).<xref ref-type="bibr" rid="article-24600.r50">[50]</xref><xref ref-type="bibr" rid="article-24600.r52">[52]</xref><xref ref-type="bibr" rid="article-24600.r54">[54]</xref>&#x000a0; Other regimens that may be considered include concurrent CRT regimens such as DeVIC with RT,&#x000a0;or VIPD with RT.<xref ref-type="bibr" rid="article-24600.r46">[46]</xref><xref ref-type="bibr" rid="article-24600.r47">[47]</xref><xref ref-type="bibr" rid="article-24600.r48">[48]</xref><xref ref-type="bibr" rid="article-24600.r49">[49]</xref></p>
        <p>
<bold>2. Response Assessment</bold>
</p>
        <p>At the end of induction therapy, patients should undergo an evaluation with PET/CT scans,&#x000a0;ear, nose, and throat examination, and EBV viral load&#x000a0;to establish remission status. Results from PET/CT scans are interpreted using the Deauville criteria.<xref ref-type="bibr" rid="article-24600.r41">[41]</xref><xref ref-type="bibr" rid="article-24600.r44">[44]</xref><xref ref-type="bibr" rid="article-24600.r45">[45]</xref><xref ref-type="bibr" rid="article-24600.r55">[55]</xref></p>
        <p>Patients with nasal disease (stage I&#x02013;II) with complete remission (disappearance of all disease) may be observed without further treatment.<xref ref-type="bibr" rid="article-24600.r56">[56]</xref>&#x000a0;In contrast, those with partial remission (regression of disease) should undergo a biopsy.<xref ref-type="bibr" rid="article-24600.r42">[42]</xref>&#x000a0;Patients with a positive biopsy should be treated as refractory disease while those with a negative biopsy may be observed without further treatment.</p>
        <p>In patients with nasal disease (stage IV) or extranasal disease (stage I&#x02013;IV), hematopoietic stem cell transplant may be considered in those with complete remission or partial remission with a negative biopsy.<xref ref-type="bibr" rid="article-24600.r57">[57]</xref><xref ref-type="bibr" rid="article-24600.r58">[58]</xref>&#x000a0;However, patients with a positive biopsy should be treated as refractory disease.<xref ref-type="bibr" rid="article-24600.r42">[42]</xref></p>
        <p>
<bold>3. Relapsed or Refractory Disease</bold>
</p>
        <p>A diagnosis of relapsed or refractory disease must be confirmed histologically by biopsy.<xref ref-type="bibr" rid="article-24600.r42">[42]</xref>&#x000a0;These patients may be treated with a second-line therapy using pegaspargase-based combination chemotherapy regimens such as AspaMetDex, modified SMILE,&#x000a0;or P-GEMOX.<xref ref-type="bibr" rid="article-24600.r50">[50]</xref><xref ref-type="bibr" rid="article-24600.r52">[52]</xref><xref ref-type="bibr" rid="article-24600.r54">[54]</xref>&#x000a0;Pembrolizumab, an anti-PD-1 monoclonal antibody, has shown remission in relapsed or refractory disease and may be considered in these patients.<xref ref-type="bibr" rid="article-24600.r59">[59]</xref>&#x000a0;Other treatment options include supportive care and participation in a clinical trial.<xref ref-type="bibr" rid="article-24600.r56">[56]</xref></p>
      </sec>
      <sec id="article-24600.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Conditions that mimic extranodal NK/T-cell lymphoma include aggressive NK-cell leukemia, nasopharyngeal carcinoma, and other mature T- and NK-cell neoplasms. Therefore, it is crucial to have an adequate biopsy with histopathological and immunohistochemical examinations to make a definitive diagnosis.</p>
      </sec>
      <sec id="article-24600.s11" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Clinical outcomes of extranodal NK/T-cell lymphoma have improved significantly with the application of modern therapies.<xref ref-type="bibr" rid="article-24600.r4">[4]</xref>&#x000a0;Nevertheless, survival is still heavily dependent on the type of disease and stage at diagnosis. In patients with nasal disease, the 5-year overall survival rate was 54%, but it was 34% in those with extranasal disease.</p>
      </sec>
      <sec id="article-24600.s12" sec-type="Complications">
        <title>Complications</title>
        <p>The most common cause of death among patients with extranodal NK/T-cell lymphoma is non-Hodgkin lymphoma, followed by other malignant cancers, heart disease, and infection.<xref ref-type="bibr" rid="article-24600.r60">[60]</xref>&#x000a0;On rare occasions, patients may present with a hemophagocytic syndrome, a rare and life-threatening disease characterized by high fever, pancytopenia, hepatosplenomegaly, liver dysfunction, coagulopathy, hyperferritinemia, and hemophagocytosis in bone marrow or other organs.<xref ref-type="bibr" rid="article-24600.r2">[2]</xref><xref ref-type="bibr" rid="article-24600.r61">[61]</xref></p>
      </sec>
      <sec id="article-24600.s13" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Being diagnosed with extranodal NK/T-cell lymphoma and undergoing treatment can have significant psychosocial impacts on patients and their families, as these can bring dramatic changes in their physical, spiritual, emotional, and interpersonal dimensions. Every clinic visit should include screening and assessment of emotional and social concerns of patients and their families. They should also be well-informed of the types of treatment, such as CRT and combination chemotherapy regimens, pros and cons of each treatment, side effects, supportive measures, and long-term management plan. Regular follow-up with primary care physicians and oncologists is also important to monitor treatment response and treatment-related toxicities.</p>
      </sec>
      <sec id="article-24600.s14" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Patient-centered teamwork approach is essential when managing patients with extranodal NK/T-cell lymphoma. An interprofessional team should work together in every step of management&#x02014;treatment of the disease, prevention and management of complications related to disease or treatment, and providing comprehensive care for patients and their families, with regular follow-ups, psychosocial support, survivorship care, and in end-of-life care.</p>
      </sec>
      <sec id="article-24600.s15">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=24600&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=24600">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/cancer/extranodal-nk-cell-lymphoma/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=24600">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/24600/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=24600">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-24600.s16">
        <fig id="article-24600.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Subcutaneous Panniculitis. High-power image of subcutaneous panniculitis, like a T-cell lymphoma showing rimming of fat cells by lymphocytes with frequent apoptotic debris (400x). Contributed by D Lynch, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="spltcl400X" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-24600.s17">
        <title>References</title>
        <ref id="article-24600.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Teras</surname>
                <given-names>LR</given-names>
              </name>
              <name>
                <surname>DeSantis</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Cerhan</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Morton</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Jemal</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Flowers</surname>
                <given-names>CR</given-names>
              </name>
            </person-group>
            <article-title>2016 US lymphoid malignancy statistics by World Health Organization subtypes.</article-title>
            <source>CA Cancer J Clin</source>
            <year>2016</year>
            <month>Nov</month>
            <day>12</day>
            <volume>66</volume>
            <issue>6</issue>
            <fpage>443</fpage>
            <page-range>443-459</page-range>
            <pub-id pub-id-type="pmid">27618563</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24600.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Au</surname>
                <given-names>WY</given-names>
              </name>
              <name>
                <surname>Weisenburger</surname>
                <given-names>DD</given-names>
              </name>
              <name>
                <surname>Intragumtornchai</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Nakamura</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>WS</given-names>
              </name>
              <name>
                <surname>Sng</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Vose</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Armitage</surname>
                <given-names>JO</given-names>
              </name>
              <name>
                <surname>Liang</surname>
                <given-names>R</given-names>
              </name>
              <collab>International Peripheral T-Cell Lymphoma Project</collab>
            </person-group>
            <article-title>Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project.</article-title>
            <source>Blood</source>
            <year>2009</year>
            <month>Apr</month>
            <day>23</day>
            <volume>113</volume>
            <issue>17</issue>
            <fpage>3931</fpage>
            <page-range>3931-7</page-range>
            <pub-id pub-id-type="pmid">19029440</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24600.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Liang</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Advances in the management and monitoring of extranodal NK/T-cell lymphoma, nasal type.</article-title>
            <source>Br J Haematol</source>
            <year>2009</year>
            <month>Oct</month>
            <volume>147</volume>
            <issue>1</issue>
            <fpage>13</fpage>
            <page-range>13-21</page-range>
            <pub-id pub-id-type="pmid">19604234</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24600.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fox</surname>
                <given-names>CP</given-names>
              </name>
              <name>
                <surname>Civallero</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ko</surname>
                <given-names>YH</given-names>
              </name>
              <name>
                <surname>Manni</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Skrypets</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Pileri</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Cabrera</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Shustov</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Chiattone</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Horwitz</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Dlouhy</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Spina</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hitz</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Montoto</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Nagler</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Martinez</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>De Souza</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Fernandez-Alvarez</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ballova</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Gab&#x000fa;s</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Inghirami</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Federico</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>WS</given-names>
              </name>
            </person-group>
            <article-title>Survival outcomes of patients with extranodal natural-killer T-cell lymphoma: a prospective cohort study from the international T-cell Project.</article-title>
            <source>Lancet Haematol</source>
            <year>2020</year>
            <month>Apr</month>
            <volume>7</volume>
            <issue>4</issue>
            <fpage>e284</fpage>
            <page-range>e284-e294</page-range>
            <pub-id pub-id-type="pmid">32105608</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24600.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Harabuchi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Yamanaka</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kataura</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Imai</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kinoshita</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Mizuno</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Osato</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Epstein-Barr virus in nasal T-cell lymphomas in patients with lethal midline granuloma.</article-title>
            <source>Lancet</source>
            <year>1990</year>
            <month>Jan</month>
            <day>20</day>
            <volume>335</volume>
            <issue>8682</issue>
            <fpage>128</fpage>
            <page-range>128-30</page-range>
            <pub-id pub-id-type="pmid">1967431</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24600.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Harabuchi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Imai</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wakashima</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hirao</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kataura</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Osato</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kon</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Nasal T-cell lymphoma causally associated with Epstein-Barr virus: clinicopathologic, phenotypic, and genotypic studies.</article-title>
            <source>Cancer</source>
            <year>1996</year>
            <month>May</month>
            <day>15</day>
            <volume>77</volume>
            <issue>10</issue>
            <fpage>2137</fpage>
            <page-range>2137-49</page-range>
            <pub-id pub-id-type="pmid">8640683</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24600.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kanavaros</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Lescs</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Bri&#x000e8;re</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Divine</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Galateau</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Joab</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Bosq</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Farcet</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Reyes</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Gaulard</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Nasal T-cell lymphoma: a clinicopathologic entity associated with peculiar phenotype and with Epstein-Barr virus.</article-title>
            <source>Blood</source>
            <year>1993</year>
            <month>May</month>
            <day>15</day>
            <volume>81</volume>
            <issue>10</issue>
            <fpage>2688</fpage>
            <page-range>2688-95</page-range>
            <pub-id pub-id-type="pmid">8387835</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24600.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Medeiros</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Jaffe</surname>
                <given-names>ES</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>YY</given-names>
              </name>
              <name>
                <surname>Weiss</surname>
                <given-names>LM</given-names>
              </name>
            </person-group>
            <article-title>Localization of Epstein-Barr viral genomes in angiocentric immunoproliferative lesions.</article-title>
            <source>Am J Surg Pathol</source>
            <year>1992</year>
            <month>May</month>
            <volume>16</volume>
            <issue>5</issue>
            <fpage>439</fpage>
            <page-range>439-47</page-range>
            <pub-id pub-id-type="pmid">1318000</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24600.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Weiss</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Gaffey</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>YY</given-names>
              </name>
              <name>
                <surname>Frierson</surname>
                <given-names>HF</given-names>
              </name>
            </person-group>
            <article-title>Frequency of Epstein-Barr viral DNA in "Western" sinonasal and Waldeyer's ring non-Hodgkin's lymphomas.</article-title>
            <source>Am J Surg Pathol</source>
            <year>1992</year>
            <month>Feb</month>
            <volume>16</volume>
            <issue>2</issue>
            <fpage>156</fpage>
            <page-range>156-62</page-range>
            <pub-id pub-id-type="pmid">1310241</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24600.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Somasundaram</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Lim</surname>
                <given-names>JQ</given-names>
              </name>
              <name>
                <surname>Ong</surname>
                <given-names>CK</given-names>
              </name>
              <name>
                <surname>Lim</surname>
                <given-names>ST</given-names>
              </name>
            </person-group>
            <article-title>Pathogenesis and biomarkers of natural killer T cell lymphoma (NKTL).</article-title>
            <source>J Hematol Oncol</source>
            <year>2019</year>
            <month>Mar</month>
            <day>15</day>
            <volume>12</volume>
            <issue>1</issue>
            <fpage>28</fpage>
            <pub-id pub-id-type="pmid">30876435</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24600.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Harabuchi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Takahara</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kishibe</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Nagato</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kumai</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type: Basic Science and Clinical Progress.</article-title>
            <source>Front Pediatr</source>
            <year>2019</year>
            <volume>7</volume>
            <fpage>141</fpage>
            <pub-id pub-id-type="pmid">31041299</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24600.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Song</surname>
                <given-names>TL</given-names>
              </name>
              <name>
                <surname>Nairism&#x000e4;gi</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Laurensia</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Lim</surname>
                <given-names>JQ</given-names>
              </name>
              <name>
                <surname>Tan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>ZM</given-names>
              </name>
              <name>
                <surname>Pang</surname>
                <given-names>WL</given-names>
              </name>
              <name>
                <surname>Kizhakeyil</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wijaya</surname>
                <given-names>GC</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Nagarajan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Chia</surname>
                <given-names>BK</given-names>
              </name>
              <name>
                <surname>Cheah</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>YH</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Rao</surname>
                <given-names>HL</given-names>
              </name>
              <name>
                <surname>Tang</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>EK</given-names>
              </name>
              <name>
                <surname>Bei</surname>
                <given-names>JX</given-names>
              </name>
              <name>
                <surname>Iqbal</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Grigoropoulos</surname>
                <given-names>NF</given-names>
              </name>
              <name>
                <surname>Ng</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Chng</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Teh</surname>
                <given-names>BT</given-names>
              </name>
              <name>
                <surname>Tan</surname>
                <given-names>SY</given-names>
              </name>
              <name>
                <surname>Verma</surname>
                <given-names>NK</given-names>
              </name>
              <name>
                <surname>Fan</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Lim</surname>
                <given-names>ST</given-names>
              </name>
              <name>
                <surname>Ong</surname>
                <given-names>CK</given-names>
              </name>
            </person-group>
            <article-title>Oncogenic activation of the STAT3 pathway drives PD-L1 expression in natural killer/T-cell lymphoma.</article-title>
            <source>Blood</source>
            <year>2018</year>
            <month>Sep</month>
            <day>13</day>
            <volume>132</volume>
            <issue>11</issue>
            <fpage>1146</fpage>
            <page-range>1146-1158</page-range>
            <pub-id pub-id-type="pmid">30054295</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24600.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Coppo</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Gouilleux-Gruart</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Bouhlal</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Bouamar</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Bouchet</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Perrot</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Vieillard</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Dartigues</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Gaulard</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Agbalika</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Douay</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Lassoued</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Gorin</surname>
                <given-names>NC</given-names>
              </name>
            </person-group>
            <article-title>STAT3 transcription factor is constitutively activated and is oncogenic in nasal-type NK/T-cell lymphoma.</article-title>
            <source>Leukemia</source>
            <year>2009</year>
            <month>Sep</month>
            <volume>23</volume>
            <issue>9</issue>
            <fpage>1667</fpage>
            <page-range>1667-78</page-range>
            <pub-id pub-id-type="pmid">19421230</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24600.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sim</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Jeon</surname>
                <given-names>YK</given-names>
              </name>
              <name>
                <surname>Nam</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Ahn</surname>
                <given-names>YO</given-names>
              </name>
              <name>
                <surname>Keam</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>HH</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>CW</given-names>
              </name>
              <name>
                <surname>Heo</surname>
                <given-names>DS</given-names>
              </name>
            </person-group>
            <article-title>Novel JAK3-Activating Mutations in Extranodal NK/T-Cell Lymphoma, Nasal Type.</article-title>
            <source>Am J Pathol</source>
            <year>2017</year>
            <month>May</month>
            <volume>187</volume>
            <issue>5</issue>
            <fpage>980</fpage>
            <page-range>980-986</page-range>
            <pub-id pub-id-type="pmid">28284718</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24600.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Keir</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Butte</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Freeman</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>Sharpe</surname>
                <given-names>AH</given-names>
              </name>
            </person-group>
            <article-title>PD-1 and its ligands in tolerance and immunity.</article-title>
            <source>Annu Rev Immunol</source>
            <year>2008</year>
            <volume>26</volume>
            <fpage>677</fpage>
            <page-range>677-704</page-range>
            <pub-id pub-id-type="pmid">18173375</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24600.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bracken</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Dietrich</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Pasini</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Hansen</surname>
                <given-names>KH</given-names>
              </name>
              <name>
                <surname>Helin</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Genome-wide mapping of Polycomb target genes unravels their roles in cell fate transitions.</article-title>
            <source>Genes Dev</source>
            <year>2006</year>
            <month>May</month>
            <day>01</day>
            <volume>20</volume>
            <issue>9</issue>
            <fpage>1123</fpage>
            <page-range>1123-36</page-range>
            <pub-id pub-id-type="pmid">16618801</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24600.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sander</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bullinger</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Klapproth</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Fiedler</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kestler</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Barth</surname>
                <given-names>TF</given-names>
              </name>
              <name>
                <surname>M&#x000f6;ller</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Stilgenbauer</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pollack</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Wirth</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>MYC stimulates EZH2 expression by repression of its negative regulator miR-26a.</article-title>
            <source>Blood</source>
            <year>2008</year>
            <month>Nov</month>
            <day>15</day>
            <volume>112</volume>
            <issue>10</issue>
            <fpage>4202</fpage>
            <page-range>4202-12</page-range>
            <pub-id pub-id-type="pmid">18713946</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24600.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ng</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Selvarajan</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Feldman</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Law</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kwong</surname>
                <given-names>YL</given-names>
              </name>
              <name>
                <surname>Shimizu</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kagami</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Aozasa</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Salto-Tellez</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Chng</surname>
                <given-names>WJ</given-names>
              </name>
            </person-group>
            <article-title>Activated oncogenic pathways and therapeutic targets in extranodal nasal-type NK/T cell lymphoma revealed by gene expression profiling.</article-title>
            <source>J Pathol</source>
            <year>2011</year>
            <month>Mar</month>
            <volume>223</volume>
            <issue>4</issue>
            <fpage>496</fpage>
            <page-range>496-510</page-range>
            <pub-id pub-id-type="pmid">21294123</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24600.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ng</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Tay</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Koh</surname>
                <given-names>TL</given-names>
              </name>
              <name>
                <surname>Tan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Selvarajan</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Bi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Choo</surname>
                <given-names>SN</given-names>
              </name>
              <name>
                <surname>Shimizu</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Chng</surname>
                <given-names>WJ</given-names>
              </name>
            </person-group>
            <article-title>EZH2 overexpression in natural killer/T-cell lymphoma confers growth advantage independently of histone methyltransferase activity.</article-title>
            <source>Blood</source>
            <year>2013</year>
            <month>May</month>
            <day>30</day>
            <volume>121</volume>
            <issue>22</issue>
            <fpage>4512</fpage>
            <page-range>4512-20</page-range>
            <pub-id pub-id-type="pmid">23529930</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24600.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>PT</given-names>
              </name>
              <name>
                <surname>Chung</surname>
                <given-names>TH</given-names>
              </name>
              <name>
                <surname>Tan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>XT</given-names>
              </name>
              <name>
                <surname>Selvarajan</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Ng</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Chng</surname>
                <given-names>WJ</given-names>
              </name>
            </person-group>
            <article-title>EZH2 phosphorylation by JAK3 mediates a switch to noncanonical function in natural killer/T-cell lymphoma.</article-title>
            <source>Blood</source>
            <year>2016</year>
            <month>Aug</month>
            <day>18</day>
            <volume>128</volume>
            <issue>7</issue>
            <fpage>948</fpage>
            <page-range>948-58</page-range>
            <pub-id pub-id-type="pmid">27297789</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24600.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kataoka</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Miyoshi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Sakata</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Dobashi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Couronn&#x000e9;</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Kogure</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Sato</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Nishida</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Gion</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Shiraishi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Tanaka</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Chiba</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Watatani</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kakiuchi</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Shiozawa</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Yoshizato</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Yoshida</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Makishima</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Sanada</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Onozawa</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Teshima</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Yoshiki</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ishida</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Suzuki</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Shimada</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Tomita</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kato</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ota</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Izutsu</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Demachi-Okamura</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Akatsuka</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Miyano</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Yoshino</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Gaulard</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Hermine</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Takeuchi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ohshima</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ogawa</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Frequent structural variations involving programmed death ligands in Epstein-Barr virus-associated lymphomas.</article-title>
            <source>Leukemia</source>
            <year>2019</year>
            <month>Jul</month>
            <volume>33</volume>
            <issue>7</issue>
            <fpage>1687</fpage>
            <page-range>1687-1699</page-range>
            <pub-id pub-id-type="pmid">30683910</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24600.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Li</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Xia</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Feng</surname>
                <given-names>LN</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Cui</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Cai</surname>
                <given-names>QQ</given-names>
              </name>
              <name>
                <surname>Sim</surname>
                <given-names>KS</given-names>
              </name>
              <name>
                <surname>Nairism&#x000e4;gi</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Laurensia</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Meah</surname>
                <given-names>WY</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>WS</given-names>
              </name>
              <name>
                <surname>Guo</surname>
                <given-names>YM</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>LZ</given-names>
              </name>
              <name>
                <surname>Feng</surname>
                <given-names>QS</given-names>
              </name>
              <name>
                <surname>Pang</surname>
                <given-names>CP</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Chew</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Ebstein</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Foo</surname>
                <given-names>JN</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ha</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Khoo</surname>
                <given-names>LP</given-names>
              </name>
              <name>
                <surname>Chin</surname>
                <given-names>ST</given-names>
              </name>
              <name>
                <surname>Zeng</surname>
                <given-names>YX</given-names>
              </name>
              <name>
                <surname>Aung</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Chowbay</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Diong</surname>
                <given-names>CP</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>YH</given-names>
              </name>
              <name>
                <surname>Tang</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Tao</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Quek</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Mohamad</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Tan</surname>
                <given-names>SY</given-names>
              </name>
              <name>
                <surname>Teh</surname>
                <given-names>BT</given-names>
              </name>
              <name>
                <surname>Ng</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Chng</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Ong</surname>
                <given-names>CK</given-names>
              </name>
              <name>
                <surname>Okada</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Raychaudhuri</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lim</surname>
                <given-names>ST</given-names>
              </name>
              <name>
                <surname>Tan</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Peng</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Khor</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Bei</surname>
                <given-names>JX</given-names>
              </name>
            </person-group>
            <article-title>Genetic risk of extranodal natural killer T-cell lymphoma: a genome-wide association study.</article-title>
            <source>Lancet Oncol</source>
            <year>2016</year>
            <month>Sep</month>
            <volume>17</volume>
            <issue>9</issue>
            <fpage>1240</fpage>
            <page-range>1240-7</page-range>
            <pub-id pub-id-type="pmid">27470079</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24600.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tien</surname>
                <given-names>HF</given-names>
              </name>
              <name>
                <surname>Su</surname>
                <given-names>IJ</given-names>
              </name>
              <name>
                <surname>Tang</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>FY</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>YC</given-names>
              </name>
              <name>
                <surname>Chuang</surname>
                <given-names>SM</given-names>
              </name>
            </person-group>
            <article-title>Clonal chromosomal abnormalities as direct evidence for clonality in nasal T/natural killer cell lymphomas.</article-title>
            <source>Br J Haematol</source>
            <year>1997</year>
            <month>Jun</month>
            <volume>97</volume>
            <issue>3</issue>
            <fpage>621</fpage>
            <page-range>621-5</page-range>
            <pub-id pub-id-type="pmid">9207410</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24600.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wong</surname>
                <given-names>KF</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Kwong</surname>
                <given-names>YL</given-names>
              </name>
            </person-group>
            <article-title>Identification of del(6)(q21q25) as a recurring chromosomal abnormality in putative NK cell lymphoma/leukaemia.</article-title>
            <source>Br J Haematol</source>
            <year>1997</year>
            <month>Sep</month>
            <volume>98</volume>
            <issue>4</issue>
            <fpage>922</fpage>
            <page-range>922-6</page-range>
            <pub-id pub-id-type="pmid">9326190</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24600.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Siu</surname>
                <given-names>LL</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>KF</given-names>
              </name>
              <name>
                <surname>Liang</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kwong</surname>
                <given-names>YL</given-names>
              </name>
            </person-group>
            <article-title>Consistent patterns of allelic loss in natural killer cell lymphoma.</article-title>
            <source>Am J Pathol</source>
            <year>2000</year>
            <month>Dec</month>
            <volume>157</volume>
            <issue>6</issue>
            <fpage>1803</fpage>
            <page-range>1803-9</page-range>
            <pub-id pub-id-type="pmid">11106552</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24600.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sun</surname>
                <given-names>HS</given-names>
              </name>
              <name>
                <surname>Su</surname>
                <given-names>IJ</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>YC</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Fang</surname>
                <given-names>SY</given-names>
              </name>
            </person-group>
            <article-title>A 2.6 Mb interval on chromosome 6q25.2-q25.3 is commonly deleted in human nasal natural killer/T-cell lymphoma.</article-title>
            <source>Br J Haematol</source>
            <year>2003</year>
            <month>Aug</month>
            <volume>122</volume>
            <issue>4</issue>
            <fpage>590</fpage>
            <page-range>590-9</page-range>
            <pub-id pub-id-type="pmid">12899714</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24600.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Takakuwa</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Dong</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Nakatsuka</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kojya</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Harabuchi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>WI</given-names>
              </name>
              <name>
                <surname>Nagata</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Aozasa</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Frequent mutations of Fas gene in nasal NK/T cell lymphoma.</article-title>
            <source>Oncogene</source>
            <year>2002</year>
            <month>Jul</month>
            <day>11</day>
            <volume>21</volume>
            <issue>30</issue>
            <fpage>4702</fpage>
            <page-range>4702-5</page-range>
            <pub-id pub-id-type="pmid">12096347</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24600.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shen</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Liang</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Au</surname>
                <given-names>WY</given-names>
              </name>
              <name>
                <surname>Kwong</surname>
                <given-names>YL</given-names>
              </name>
              <name>
                <surname>Liang</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Srivastava</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Frequent deletion of Fas gene sequences encoding death and transmembrane domains in nasal natural killer/T-cell lymphoma.</article-title>
            <source>Am J Pathol</source>
            <year>2002</year>
            <month>Dec</month>
            <volume>161</volume>
            <issue>6</issue>
            <fpage>2123</fpage>
            <page-range>2123-31</page-range>
            <pub-id pub-id-type="pmid">12466128</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24600.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Takahara</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kishibe</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Bandoh</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Nonaka</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Harabuchi</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>P53, N- and K-Ras, and beta-catenin gene mutations and prognostic factors in nasal NK/T-cell lymphoma from Hokkaido, Japan.</article-title>
            <source>Hum Pathol</source>
            <year>2004</year>
            <month>Jan</month>
            <volume>35</volume>
            <issue>1</issue>
            <fpage>86</fpage>
            <page-range>86-95</page-range>
            <pub-id pub-id-type="pmid">14745729</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24600.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hongyo</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Hoshida</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Nakatsuka</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Syaifudin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kojya</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>WI</given-names>
              </name>
              <name>
                <surname>Min</surname>
                <given-names>YH</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Harabuchi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Himi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Inuyama</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Aozasa</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Nomura</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>p53, K-ras, c-kit and beta-catenin gene mutations in sinonasal NK/T-cell lymphoma in Korea and Japan.</article-title>
            <source>Oncol Rep</source>
            <year>2005</year>
            <month>Feb</month>
            <volume>13</volume>
            <issue>2</issue>
            <fpage>265</fpage>
            <page-range>265-71</page-range>
            <pub-id pub-id-type="pmid">15643509</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24600.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Li</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Hongyo</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Syaifudin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nomura</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Dong</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Shingu</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kojya</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Nakatsuka</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Aozasa</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Mutations of the p53 gene in nasal NK/T-cell lymphoma.</article-title>
            <source>Lab Invest</source>
            <year>2000</year>
            <month>Apr</month>
            <volume>80</volume>
            <issue>4</issue>
            <fpage>493</fpage>
            <page-range>493-9</page-range>
            <pub-id pub-id-type="pmid">10780666</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24600.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hoshida</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Hongyo</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Jia</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>He</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Hasui</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Dong</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Luo</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Ham</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Nomura</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Aozasa</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Analysis of p53, K-ras, c-kit, and beta-catenin gene mutations in sinonasal NK/T cell lymphoma in northeast district of China.</article-title>
            <source>Cancer Sci</source>
            <year>2003</year>
            <month>Mar</month>
            <volume>94</volume>
            <issue>3</issue>
            <fpage>297</fpage>
            <page-range>297-301</page-range>
            <pub-id pub-id-type="pmid">12824925</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24600.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Quintanilla-Martinez</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Kremer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Keller</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Nathrath</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gamboa-Dominguez</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Meneses</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Luna-Contreras</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Cabras</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hoefler</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Mohar</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fend</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>p53 Mutations in nasal natural killer/T-cell lymphoma from Mexico: association with large cell morphology and advanced disease.</article-title>
            <source>Am J Pathol</source>
            <year>2001</year>
            <month>Dec</month>
            <volume>159</volume>
            <issue>6</issue>
            <fpage>2095</fpage>
            <page-range>2095-105</page-range>
            <pub-id pub-id-type="pmid">11733360</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24600.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Peng</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Han</surname>
                <given-names>BW</given-names>
              </name>
              <name>
                <surname>Cai</surname>
                <given-names>QQ</given-names>
              </name>
              <name>
                <surname>Zuo</surname>
                <given-names>XY</given-names>
              </name>
              <name>
                <surname>Xia</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Feng</surname>
                <given-names>LN</given-names>
              </name>
              <name>
                <surname>Lim</surname>
                <given-names>JQ</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Zeng</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Guo</surname>
                <given-names>YM</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Xia</surname>
                <given-names>XJ</given-names>
              </name>
              <name>
                <surname>Xia</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Laurensia</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Chia</surname>
                <given-names>BKH</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>HQ</given-names>
              </name>
              <name>
                <surname>Young</surname>
                <given-names>KH</given-names>
              </name>
              <name>
                <surname>Lim</surname>
                <given-names>ST</given-names>
              </name>
              <name>
                <surname>Ong</surname>
                <given-names>CK</given-names>
              </name>
              <name>
                <surname>Zeng</surname>
                <given-names>YX</given-names>
              </name>
              <name>
                <surname>Bei</surname>
                <given-names>JX</given-names>
              </name>
            </person-group>
            <article-title>Genomic and transcriptomic landscapes of Epstein-Barr virus in extranodal natural killer T-cell lymphoma.</article-title>
            <source>Leukemia</source>
            <year>2019</year>
            <month>Jun</month>
            <volume>33</volume>
            <issue>6</issue>
            <fpage>1451</fpage>
            <page-range>1451-1462</page-range>
            <pub-id pub-id-type="pmid">30546078</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24600.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gru</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Haverkos</surname>
                <given-names>BH</given-names>
              </name>
              <name>
                <surname>Freud</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Hastings</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Nowacki</surname>
                <given-names>NB</given-names>
              </name>
              <name>
                <surname>Barrionuevo</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Vigil</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Rochford</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Natkunam</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Baiocchi</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Porcu</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>The Epstein-Barr Virus (EBV) in T Cell and NK Cell Lymphomas: Time for a Reassessment.</article-title>
            <source>Curr Hematol Malig Rep</source>
            <year>2015</year>
            <month>Dec</month>
            <volume>10</volume>
            <issue>4</issue>
            <fpage>456</fpage>
            <page-range>456-67</page-range>
            <pub-id pub-id-type="pmid">26449716</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24600.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Moriai</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Takahara</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ogino</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Nagato</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kishibe</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ishii</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Katayama</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Shimizu</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Harabuchi</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Production of interferon-{gamma}-inducible protein-10 and its role as an autocrine invasion factor in nasal natural killer/T-cell lymphoma cells.</article-title>
            <source>Clin Cancer Res</source>
            <year>2009</year>
            <month>Nov</month>
            <day>15</day>
            <volume>15</volume>
            <issue>22</issue>
            <fpage>6771</fpage>
            <page-range>6771-9</page-range>
            <pub-id pub-id-type="pmid">19887486</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24600.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kumai</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Nagato</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kobayashi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Komabayashi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ueda</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kishibe</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ohkuri</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Takahara</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Celis</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Harabuchi</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>CCL17 and CCL22/CCR4 signaling is a strong candidate for novel targeted therapy against nasal natural killer/T-cell lymphoma.</article-title>
            <source>Cancer Immunol Immunother</source>
            <year>2015</year>
            <month>Jun</month>
            <volume>64</volume>
            <issue>6</issue>
            <fpage>697</fpage>
            <page-range>697-705</page-range>
            <pub-id pub-id-type="pmid">25754123</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24600.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pongpruttipan</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Sukpanichnant</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Assanasen</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Wannakrairot</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Boonsakan</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kanoksil</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Kayasut</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Mitarnun</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Khuhapinant</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bunworasate</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Puavilai</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Bedavanija</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Garcia-Herrera</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Campo</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Cook</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Choi</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Swerdlow</surname>
                <given-names>SH</given-names>
              </name>
            </person-group>
            <article-title>Extranodal NK/T-cell lymphoma, nasal type, includes cases of natural killer cell and &#x003b1;&#x003b2;, &#x003b3;&#x003b4;, and &#x003b1;&#x003b2;/&#x003b3;&#x003b4; T-cell origin: a comprehensive clinicopathologic and phenotypic study.</article-title>
            <source>Am J Surg Pathol</source>
            <year>2012</year>
            <month>Apr</month>
            <volume>36</volume>
            <issue>4</issue>
            <fpage>481</fpage>
            <page-range>481-99</page-range>
            <pub-id pub-id-type="pmid">22314189</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24600.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wong</surname>
                <given-names>KF</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Cheung</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>So</surname>
                <given-names>JC</given-names>
              </name>
            </person-group>
            <article-title>Bone marrow involvement by nasal NK cell lymphoma at diagnosis is uncommon.</article-title>
            <source>Am J Clin Pathol</source>
            <year>2001</year>
            <month>Feb</month>
            <volume>115</volume>
            <issue>2</issue>
            <fpage>266</fpage>
            <page-range>266-70</page-range>
            <pub-id pub-id-type="pmid">11211616</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24600.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kim</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Jung</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Chuang</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Hong</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Guo</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Cao</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hong</surname>
                <given-names>XN</given-names>
              </name>
              <name>
                <surname>Suzuki</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kang</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Won</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Chng</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Kwong</surname>
                <given-names>YL</given-names>
              </name>
              <name>
                <surname>Suh</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Song</surname>
                <given-names>YQ</given-names>
              </name>
              <name>
                <surname>Zhu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Tay</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Lim</surname>
                <given-names>ST</given-names>
              </name>
              <name>
                <surname>Suzumiya</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>TY</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>WS</given-names>
              </name>
              <collab>Asia Lymphoma Study Group</collab>
            </person-group>
            <article-title>Extranodal natural killer/T-cell lymphoma involving the gastrointestinal tract: analysis of clinical features and outcomes from the Asia Lymphoma Study Group.</article-title>
            <source>J Hematol Oncol</source>
            <year>2013</year>
            <month>Nov</month>
            <day>16</day>
            <volume>6</volume>
            <fpage>86</fpage>
            <pub-id pub-id-type="pmid">24238138</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24600.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ding</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>YL</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Positron emission tomography/computed tomography in the diagnosis, staging, and prognostic evaluation of natural killer/T-cell lymphoma.</article-title>
            <source>J Int Med Res</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>46</volume>
            <issue>12</issue>
            <fpage>4920</fpage>
            <page-range>4920-4929</page-range>
            <pub-id pub-id-type="pmid">30328364</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24600.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cheson</surname>
                <given-names>BD</given-names>
              </name>
              <name>
                <surname>Fisher</surname>
                <given-names>RI</given-names>
              </name>
              <name>
                <surname>Barrington</surname>
                <given-names>SF</given-names>
              </name>
              <name>
                <surname>Cavalli</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Schwartz</surname>
                <given-names>LH</given-names>
              </name>
              <name>
                <surname>Zucca</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Lister</surname>
                <given-names>TA</given-names>
              </name>
              <collab>Alliance, Australasian Leukaemia and Lymphoma Group</collab>
              <collab>Eastern Cooperative Oncology Group</collab>
              <collab>European Mantle Cell Lymphoma Consortium</collab>
              <collab>Italian Lymphoma Foundation</collab>
              <collab>European Organisation for Research</collab>
              <collab>Treatment of Cancer/Dutch Hemato-Oncology Group</collab>
              <collab>Grupo Espa&#x000f1;ol de M&#x000e9;dula &#x000d3;sea</collab>
              <collab>German High-Grade Lymphoma Study Group</collab>
              <collab>German Hodgkin's Study Group</collab>
              <collab>Japanese Lymphorra Study Group</collab>
              <collab>Lymphoma Study Association</collab>
              <collab>NCIC Clinical Trials Group</collab>
              <collab>Nordic Lymphoma Study Group</collab>
              <collab>Southwest Oncology Group</collab>
              <collab>United Kingdom National Cancer Research Institute</collab>
            </person-group>
            <article-title>Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification.</article-title>
            <source>J Clin Oncol</source>
            <year>2014</year>
            <month>Sep</month>
            <day>20</day>
            <volume>32</volume>
            <issue>27</issue>
            <fpage>3059</fpage>
            <page-range>3059-68</page-range>
            <pub-id pub-id-type="pmid">25113753</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24600.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kim</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Yoon</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>Jaccard</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Chng</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Lim</surname>
                <given-names>ST</given-names>
              </name>
              <name>
                <surname>Hong</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Maeda</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ishida</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Shin</surname>
                <given-names>DY</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Jeong</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>Jo</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>GW</given-names>
              </name>
              <name>
                <surname>Choi</surname>
                <given-names>CW</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>WS</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>TY</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Jung</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Murayama</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Oki</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Advani</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>d'Amore</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Schmitz</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Suh</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Suzuki</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kwong</surname>
                <given-names>YL</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>TY</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>WS</given-names>
              </name>
            </person-group>
            <article-title>A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis.</article-title>
            <source>Lancet Oncol</source>
            <year>2016</year>
            <month>Mar</month>
            <volume>17</volume>
            <issue>3</issue>
            <fpage>389</fpage>
            <page-range>389-400</page-range>
            <pub-id pub-id-type="pmid">26873565</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24600.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Au</surname>
                <given-names>WY</given-names>
              </name>
              <name>
                <surname>Pang</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Choy</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Chim</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Kwong</surname>
                <given-names>YL</given-names>
              </name>
            </person-group>
            <article-title>Quantification of circulating Epstein-Barr virus (EBV) DNA in the diagnosis and monitoring of natural killer cell and EBV-positive lymphomas in immunocompetent patients.</article-title>
            <source>Blood</source>
            <year>2004</year>
            <month>Jul</month>
            <day>01</day>
            <volume>104</volume>
            <issue>1</issue>
            <fpage>243</fpage>
            <page-range>243-9</page-range>
            <pub-id pub-id-type="pmid">15031209</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24600.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kim</surname>
                <given-names>HS</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>KH</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>KH</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Ji</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Lim</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Ko</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ki</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Jo</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>WS</given-names>
              </name>
            </person-group>
            <article-title>Whole blood Epstein-Barr virus DNA load as a diagnostic and prognostic surrogate: extranodal natural killer/T-cell lymphoma.</article-title>
            <source>Leuk Lymphoma</source>
            <year>2009</year>
            <month>May</month>
            <volume>50</volume>
            <issue>5</issue>
            <fpage>757</fpage>
            <page-range>757-63</page-range>
            <pub-id pub-id-type="pmid">19330658</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24600.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yamaguchi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tobinai</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Oguchi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ishizuka</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kobayashi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Isobe</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ishizawa</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Maseki</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Itoh</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Usui</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Wasada</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Kinoshita</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ohshima</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Matsuno</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Terauchi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Nawano</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ishikura</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kagami</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Hotta</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Oshimi</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Phase I/II study of concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: Japan Clinical Oncology Group Study JCOG0211.</article-title>
            <source>J Clin Oncol</source>
            <year>2009</year>
            <month>Nov</month>
            <day>20</day>
            <volume>27</volume>
            <issue>33</issue>
            <fpage>5594</fpage>
            <page-range>5594-600</page-range>
            <pub-id pub-id-type="pmid">19805668</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24600.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yamaguchi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tobinai</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Oguchi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ishizuka</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kobayashi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Isobe</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ishizawa</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Maseki</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Itoh</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Usui</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Wasada</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Kinoshita</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Hotta</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Tsukasaki</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Oshimi</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: an updated analysis of the Japan clinical oncology group study JCOG0211.</article-title>
            <source>J Clin Oncol</source>
            <year>2012</year>
            <month>Nov</month>
            <day>10</day>
            <volume>30</volume>
            <issue>32</issue>
            <fpage>4044</fpage>
            <page-range>4044-6</page-range>
            <pub-id pub-id-type="pmid">23045573</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24600.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yamaguchi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Suzuki</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Oguchi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Asano</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Amaki</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Akiba</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Maeda</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Itasaka</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kubota</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Saito</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kobayashi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Itami</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ueda</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Miyazaki</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ii</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Tomita</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Sekiguchi</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Takizawa</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Saito</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Murayama</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ando</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Wada</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Hyo</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ejima</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Hasegawa</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Katayama</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Treatments and Outcomes of Patients With Extranodal Natural Killer/T-Cell Lymphoma Diagnosed Between 2000 and 2013: A Cooperative Study in Japan.</article-title>
            <source>J Clin Oncol</source>
            <year>2017</year>
            <month>Jan</month>
            <volume>35</volume>
            <issue>1</issue>
            <fpage>32</fpage>
            <page-range>32-39</page-range>
            <pub-id pub-id-type="pmid">28034070</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24600.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kim</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>BS</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>CY</given-names>
              </name>
              <name>
                <surname>Suh</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Huh</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Cho</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>GW</given-names>
              </name>
              <name>
                <surname>Kang</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Eom</surname>
                <given-names>HS</given-names>
              </name>
              <name>
                <surname>Pyo</surname>
                <given-names>HR</given-names>
              </name>
              <name>
                <surname>Ahn</surname>
                <given-names>YC</given-names>
              </name>
              <name>
                <surname>Ko</surname>
                <given-names>YH</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>WS</given-names>
              </name>
            </person-group>
            <article-title>Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK/T-Cell Lymphoma: Consortium for Improving Survival of Lymphoma study.</article-title>
            <source>J Clin Oncol</source>
            <year>2009</year>
            <month>Dec</month>
            <day>10</day>
            <volume>27</volume>
            <issue>35</issue>
            <fpage>6027</fpage>
            <page-range>6027-32</page-range>
            <pub-id pub-id-type="pmid">19884539</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24600.r50">
          <label>50</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Qi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Yahalom</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hsu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Chelius</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lunning</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Moskowitz</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Horwitz</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Encouraging experience in the treatment of nasal type extra-nodal NK/T-cell lymphoma in a non-Asian population.</article-title>
            <source>Leuk Lymphoma</source>
            <year>2016</year>
            <month>Nov</month>
            <volume>57</volume>
            <issue>11</issue>
            <fpage>2575</fpage>
            <page-range>2575-83</page-range>
            <pub-id pub-id-type="pmid">27183991</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24600.r51">
          <label>51</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wei</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>ZH</given-names>
              </name>
            </person-group>
            <article-title>Effectiveness of pegaspargase, gemcitabine, and oxaliplatin (P-GEMOX) chemotherapy combined with radiotherapy in newly diagnosed, stage IE to IIE, nasal-type, extranodal natural killer/T-cell lymphoma.</article-title>
            <source>Hematology</source>
            <year>2017</year>
            <month>Jul</month>
            <volume>22</volume>
            <issue>6</issue>
            <fpage>320</fpage>
            <page-range>320-329</page-range>
            <pub-id pub-id-type="pmid">27917702</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24600.r52">
          <label>52</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jing</surname>
                <given-names>XM</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>ZH</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Ren</surname>
                <given-names>YR</given-names>
              </name>
              <name>
                <surname>Xiong</surname>
                <given-names>ZJ</given-names>
              </name>
              <name>
                <surname>Wei</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Luo</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Efficacy and tolerance of pegaspargase, gemcitabine and oxaliplatin with sandwiched radiotherapy in the treatment of newly-diagnosed extranodal nature killer (NK)/T cell lymphoma.</article-title>
            <source>Leuk Res</source>
            <year>2016</year>
            <month>Aug</month>
            <volume>47</volume>
            <fpage>26</fpage>
            <page-range>26-31</page-range>
            <pub-id pub-id-type="pmid">27239738</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24600.r53">
          <label>53</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>YX</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>WH</given-names>
              </name>
              <name>
                <surname>Jin</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Dai</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>YP</given-names>
              </name>
              <name>
                <surname>Song</surname>
                <given-names>YW</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>ZY</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>QF</given-names>
              </name>
              <name>
                <surname>Fang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Qi</surname>
                <given-names>SN</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>XF</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>ZH</given-names>
              </name>
            </person-group>
            <article-title>Mild toxicity and favorable prognosis of high-dose and extended involved-field intensity-modulated radiotherapy for patients with early-stage nasal NK/T-cell lymphoma.</article-title>
            <source>Int J Radiat Oncol Biol Phys</source>
            <year>2012</year>
            <month>Mar</month>
            <day>01</day>
            <volume>82</volume>
            <issue>3</issue>
            <fpage>1115</fpage>
            <page-range>1115-21</page-range>
            <pub-id pub-id-type="pmid">21514070</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24600.r54">
          <label>54</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jaccard</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gachard</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Marin</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Rogez</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Audrain</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Suarez</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Tilly</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Morschhauser</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Thieblemont</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ysebaert</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Devidas</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Petit</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>de Leval</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Gaulard</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Feuillard</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bordessoule</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Hermine</surname>
                <given-names>O</given-names>
              </name>
              <collab>GELA and GOELAMS Intergroup</collab>
            </person-group>
            <article-title>Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study.</article-title>
            <source>Blood</source>
            <year>2011</year>
            <month>Feb</month>
            <day>10</day>
            <volume>117</volume>
            <issue>6</issue>
            <fpage>1834</fpage>
            <page-range>1834-9</page-range>
            <pub-id pub-id-type="pmid">21123825</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24600.r55">
          <label>55</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Barrington</surname>
                <given-names>SF</given-names>
              </name>
              <name>
                <surname>Mikhaeel</surname>
                <given-names>NG</given-names>
              </name>
              <name>
                <surname>Kostakoglu</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Meignan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hutchings</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>M&#x000fc;eller</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Schwartz</surname>
                <given-names>LH</given-names>
              </name>
              <name>
                <surname>Zucca</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Fisher</surname>
                <given-names>RI</given-names>
              </name>
              <name>
                <surname>Trotman</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hoekstra</surname>
                <given-names>OS</given-names>
              </name>
              <name>
                <surname>Hicks</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>O'Doherty</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Hustinx</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Biggi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cheson</surname>
                <given-names>BD</given-names>
              </name>
            </person-group>
            <article-title>Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group.</article-title>
            <source>J Clin Oncol</source>
            <year>2014</year>
            <month>Sep</month>
            <day>20</day>
            <volume>32</volume>
            <issue>27</issue>
            <fpage>3048</fpage>
            <page-range>3048-58</page-range>
            <pub-id pub-id-type="pmid">25113771</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24600.r56">
          <label>56</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Horwitz</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Ansell</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Ai</surname>
                <given-names>WZ</given-names>
              </name>
              <name>
                <surname>Barnes</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Barta</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Choi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Clemens</surname>
                <given-names>MW</given-names>
              </name>
              <name>
                <surname>Dogan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Greer</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Halwani</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Haverkos</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Hoppe</surname>
                <given-names>RT</given-names>
              </name>
              <name>
                <surname>Jacobsen</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Jagadeesh</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>YH</given-names>
              </name>
              <name>
                <surname>Lunning</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Mehta</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mehta-Shah</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Oki</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Olsen</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Pro</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Rajguru</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Shanbhag</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Shustov</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sokol</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Torka</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Wilcox</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>William</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Zain</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Dwyer</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Sundar</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>NCCN Guidelines Insights: T-Cell Lymphomas, Version 2.2018.</article-title>
            <source>J Natl Compr Canc Netw</source>
            <year>2018</year>
            <month>Feb</month>
            <volume>16</volume>
            <issue>2</issue>
            <fpage>123</fpage>
            <page-range>123-135</page-range>
            <pub-id pub-id-type="pmid">29439173</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24600.r57">
          <label>57</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yhim</surname>
                <given-names>HY</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Mun</surname>
                <given-names>YC</given-names>
              </name>
              <name>
                <surname>Moon</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Chae</surname>
                <given-names>YS</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Jo</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Yoon</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>Cheong</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Kwak</surname>
                <given-names>JY</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>WS</given-names>
              </name>
              <name>
                <surname>Suh</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>DH</given-names>
              </name>
              <collab>Consortium for Improving Survival of Lymphoma Study</collab>
            </person-group>
            <article-title>Clinical Outcomes and Prognostic Factors of Up-Front Autologous Stem Cell Transplantation in Patients with Extranodal Natural Killer/T Cell Lymphoma.</article-title>
            <source>Biol Blood Marrow Transplant</source>
            <year>2015</year>
            <month>Sep</month>
            <volume>21</volume>
            <issue>9</issue>
            <fpage>1597</fpage>
            <page-range>1597-604</page-range>
            <pub-id pub-id-type="pmid">25963920</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24600.r58">
          <label>58</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tse</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>TS</given-names>
              </name>
              <name>
                <surname>Koh</surname>
                <given-names>LP</given-names>
              </name>
              <name>
                <surname>Chng</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>WS</given-names>
              </name>
              <name>
                <surname>Tang</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Lim</surname>
                <given-names>ST</given-names>
              </name>
              <name>
                <surname>Lie</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Kwong</surname>
                <given-names>YL</given-names>
              </name>
            </person-group>
            <article-title>Allogeneic haematopoietic SCT for natural killer/T-cell lymphoma: a multicentre analysis from the Asia Lymphoma Study Group.</article-title>
            <source>Bone Marrow Transplant</source>
            <year>2014</year>
            <month>Jul</month>
            <volume>49</volume>
            <issue>7</issue>
            <fpage>902</fpage>
            <page-range>902-6</page-range>
            <pub-id pub-id-type="pmid">24777195</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24600.r59">
          <label>59</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kwong</surname>
                <given-names>YL</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>TSY</given-names>
              </name>
              <name>
                <surname>Tan</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Poon</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Mow</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Khong</surname>
                <given-names>PL</given-names>
              </name>
              <name>
                <surname>Loong</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Au-Yeung</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Iqbal</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Phipps</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Tse</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell lymphoma failing l-asparaginase.</article-title>
            <source>Blood</source>
            <year>2017</year>
            <month>Apr</month>
            <day>27</day>
            <volume>129</volume>
            <issue>17</issue>
            <fpage>2437</fpage>
            <page-range>2437-2442</page-range>
            <pub-id pub-id-type="pmid">28188133</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24600.r60">
          <label>60</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mei</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Causes of mortality in cases with extra nodal natural killer/T-cell lymphoma, nasal type: A cohort study.</article-title>
            <source>PLoS One</source>
            <year>2019</year>
            <volume>14</volume>
            <issue>4</issue>
            <fpage>e0214860</fpage>
            <pub-id pub-id-type="pmid">30995261</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24600.r61">
          <label>61</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Han</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Fu</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Ma</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Sun</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Guo</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Clinical features and treatment of natural killer/T cell lymphoma associated with hemophagocytic syndrome: comparison with other T cell lymphoma associated with hemophagocytic syndrome.</article-title>
            <source>Leuk Lymphoma</source>
            <year>2014</year>
            <month>Sep</month>
            <volume>55</volume>
            <issue>9</issue>
            <fpage>2048</fpage>
            <page-range>2048-55</page-range>
            <pub-id pub-id-type="pmid">24359240</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
